NCT03130127View on ClinicalTrials.gov

Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions

Liver CirrhosisPortal HypertensionVariceal HemorrhageBleedingEsophageal and Gastric Varices

Interventions

DRUG

Terlipressin

According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.

All Listed Sponsors

lead

General Hospital of Shenyang Military Region

OTHER

NCT03130127 - Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis | Biotech Hunter | Biotech Hunter